Loading...
Oxybutynin is commonly used for overactive bladder and for hot flashes in women. Could it also help with hot flashes among men receiving androgen-deprivation therapy (ADT) for prostate cancer? To find out, researchers randomized 88 men on ADT who were experiencing at least 28 hot flashes per week to receive oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks.
Patients receiving oxybutynin had a significantly greater decline in daily hot flash frequency than those receiving placebo. About 60% of the low-dose group and 80% of the higher-dose group had a clinically meaningful (≥50%) reduction in hot flash burden.
Hot flash–related quality-of-life scores improved significantly more with ox…